These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25596665)

  • 1. Limited impact of drug exposure misclassification from non-benefit thiazolidinedione drug use on mortality and hospitalizations from Saskatchewan, Canada: a cohort study.
    Gamble JM; Johnson JA; McAlister FA; Majumdar SR; Simpson SH; Eurich DT
    Clin Ther; 2015 Mar; 37(3):629-42. PubMed ID: 25596665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the introduction of a computerized prior-authorization system on the completeness of drug exposure data.
    Gamble JM; Johnson JA; Majumdar SR; McAlister FA; Simpson SH; Eurich DT
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):551-5. PubMed ID: 23475736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the impact of drug exposure misclassification due to restrictive drug coverage in administrative databases: a simulation cohort study.
    Gamble JM; McAlister FA; Johnson JA; Eurich DT
    Value Health; 2012 Jan; 15(1):191-7. PubMed ID: 22264988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in thiazolidinedione use and outcomes following removal of a prior-authorization policy: controlled time-series analysis.
    Gamble JM; Majumdar SR; Johnson JA; McAlister FA; Simpson SH; Eurich DT
    Med Care; 2014 Jan; 52(1):47-55. PubMed ID: 24309670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis.
    Yen FS; Wei JC; Chiu LT; Hsu CC; Hou MC; Hwu CM
    Liver Int; 2021 Jan; 41(1):110-122. PubMed ID: 33124143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immeasurable time bias due to hospitalization in medico-administrative databases: which impact for pharmacoepidemiological studies?
    Palmaro A; Boucherie Q; Dupouy J; Micallef J; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):544-553. PubMed ID: 28266748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study.
    Ward A; Ishak K; Proskorovsky I; Caro J
    Clin Ther; 2006 Nov; 28(11):1912-21. PubMed ID: 17213012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
    Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
    Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.
    Lin HC; Hsu YT; Kachingwe BH; Hsu CY; Uang YS; Wang LH
    J Clin Pharm Ther; 2014 Aug; 39(4):354-60. PubMed ID: 24661226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan.
    Yeh HT; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2012 Apr; 34(4):885-93. PubMed ID: 22440193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
    Stockl KM; Le L; Zhang S; Harada AS
    Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinedione use is not associated with worse cardiovascular outcomes: a study in 28,332 high risk patients with diabetes in routine clinical practice: brief title: thiazolidinedione use and mortality.
    Roussel R; Hadjadj S; Pasquet B; Wilson PW; Smith SC; Goto S; Tubach F; Marre M; Porath A; Krempf M; Bhatt DL; Steg PG
    Int J Cardiol; 2013 Aug; 167(4):1380-4. PubMed ID: 22560911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restrictive drug coverage policies can induce substantial drug exposure misclassification in pharmacoepidemiologic studies.
    Gamble JM; McAlister FA; Johnson JA; Eurich DT
    Clin Ther; 2012 Jun; 34(6):1379-1386.e3. PubMed ID: 22554975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
    Bazelier MT; Gallagher AM; van Staa TP; Cooper C; Leufkens HG; Vestergaard P; de Vries F
    Pharmacoepidemiol Drug Saf; 2012 May; 21(5):507-14. PubMed ID: 22392882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
    Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
    Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes.
    Yen FS; Yang YC; Hwu CM; Wei JC; Huang YH; Hou MC; Hsu CC
    Liver Int; 2020 May; 40(5):1089-1097. PubMed ID: 31960563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis.
    Balkrishnan R; Rajagopalan R; Shenolikar RA; Camacho FT; Anderson RT
    Curr Med Res Opin; 2006 Mar; 22(3):551-9. PubMed ID: 16574038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.